Results 81 to 90 of about 34,871 (236)

Occupational burnout in nuclear medicine technologists working in Australia and New Zealand – results of a multi‐national survey

open access: yesJournal of Medical Radiation Sciences, Volume 72, Issue 1, Page 25-33, March 2025.
Occupational burnout is associated with negative feelings about the workplace and is often caused by a high workload and a non‐supportive workplace. It is associated with absenteeism, high turnover of staff and decreased patient care. More than half of the New Zealand participants and three quarters of the Australian participants had moderate levels of
Melissa Shields   +2 more
wiley   +1 more source

Molecular theranostics: principles, challenges and controversies

open access: yesJournal of Medical Radiation Sciences, Volume 72, Issue 1, Page 156-164, March 2025.
Molecular theranostics offers a powerful tool to drive precision medicine in nuclear oncology. While theranostics is not a new principle in nuclear medicine, recent advances in instrumentation and radiopharmacy have driven a reinvigoration and a broader suite of applications.
Geoffrey Currie
wiley   +1 more source

Novel [99mTcN]2+ Labeled EGFR Inhibitors as Potential Radiotracers for Single Photon Emission Computed Tomography (SPECT) Tumor Imaging

open access: yesMolecules, 2014
The epidermal growth factor receptor (EGFR) is overexpressed in many cancers, including breast, ovarian, endometrial and non-small cell lung cancer. An EGFR-specific imaging agent could facilitate clinical evaluation of primary tumors or metastases.
Mingxia Zhao   +5 more
doaj   +1 more source

Alzheimer's Biomarkers and Visuospatial Cognition in Parkinson's Disease: Modification by α‐Synuclein and Mediation of Age Effects

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Visuospatial deficits in Parkinson's disease (PD) often precede dementia and complicate daily functioning. Alzheimer's disease (AD) pathology and α‐synuclein aggregation frequently co‐occur in PD, but their combined impact on cognition is unclear.
David Ledingham   +8 more
wiley   +1 more source

Assessment of cell damage produced by 161Tb-/177Lu-somatostatin analog radiopharmaceuticals [PDF]

open access: yes, 2023
The use of 161Tb has been proposed for targeted radionuclide therapy (TRT) because its decay properties are quite similar to those of 177Lu, which is currently the most used radionuclide in TRT.
Guillermina Ferro-Flores   +5 more
core  

Clinical Progression in Alpha‐Synuclein Positive LRRK2‐PD and Sporadic Parkinson's Disease: A Longitudinal Analysis

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background LRRK2‐Parkinson's disease (LRRK2‐PD) is biologically heterogeneous with approximately 30% lacking aggregated alpha synuclein (αSyn) in cerebrospinal fluid by seed amplification assay (SAA). Prior work has suggested slower progression in LRRK2‐PD compared to sporadic PD (sPD).
Lucy A. Morse   +224 more
wiley   +1 more source

Sex Differences in Fall Frequency, Risk Factors, and Outcomes in Parkinson's Disease: A Cross‐Sectional Analysis

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Female sex is an independent fall risk factor in Parkinson's disease (PD), yet sex‐specific fall patterns remain unclear. Objectives To compare sex‐specific fall risk and outcomes across PD, prodromal alpha‐synucleinopathy (PAS), and healthy controls (HC); estimate fall frequency across PD progression; and assess how sex modifies ...
Joaquin A. Vizcarra   +197 more
wiley   +1 more source

Disease‐Duration–Specific Percentiles for Prospective Subtyping of Parkinson's Disease: A PPMI‐Based Study

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is clinically heterogeneous, with variable progression rates that complicate clinical trial design. The data‐driven diffuse malignant (DM), intermediate (IM), and mild‐motor predominant (MMP) subtyping model has prognostic value but lacks disease duration–specific thresholds for prospective use in disease ...
Ahmed Negida   +4 more
wiley   +1 more source

Radiopharmaceuticals for diagnosis. Final report [PDF]

open access: yes, 1994
In the period 1969-1986, this project was directed to the evolution of target-specific labeled chemicals useful for nuclear medical imaging, especially radioactive indicators suited to tracing adrenal functions and localizing tumors in the neuroendocrine

core   +1 more source

Oligonucleotides as Radiopharmaceuticals

open access: yes, 2006
Oligonucleotide radiopharmaceuticals is a slowly but steadily progressing field. With a panel of labeling and imaging techniques mastered by several groups, imaging of oligonucleotides is now relatively accessible and will be applied to more and more trials of oligonucleotide pharmacology.
openaire   +2 more sources

Home - About - Disclaimer - Privacy